Abstract: Provided herein is a Magnetic Resonance Imaging (MRI) technique and, optionally, software, collectively referred to as the “shutter-speed” model, to analyze image data of cancer patients. Embodiments provide a minimally invasive, yet precisely accurate, approach to determining whether tumors are malignant or benign by distinguishing the characteristics of contrast reagent activity in benign and malignant tumors. Exemplary embodiments provide MRI measured biomarkers for tumor malignancy determination and monitoring, effectively eliminating or limiting the false positives suffered by existing MRI techniques while also improving tissue phenotyping and therapeutic intervention monitoring and prediction.

Abstract: Embodiments provide a Magnetic Resonance Imaging (MRI) technique and optionally software—collectively referred to as the “shutter-speed” model—to analyze image data of cancer patients. Embodiments provide a minimally invasive, yet precisely accurate, approach to determining whether tumors are malignant or benign by distinguishing the characteristics of contrast reagent activity in benign and malignant tumors. Exemplary embodiments provide MRI measured biomarkers for tumor malignancy determination, effectively eliminating or limiting the false positives suffered by existing MRI techniques.

Abstract: Embodiments provide a Magnetic Resonance Imaging (MRI) technique and optionally software—collectively referred to as the “shutter-speed” model—to analyze image data of cancer patients. Embodiments provide a minimally invasive, yet precisely accurate, approach to determining whether tumors are malignant or benign by distinguishing the characteristics of contrast reagent activity in benign and malignant tumors. Exemplary embodiments provide MRI measured biomarkers for tumor malignancy determination, effectively eliminating or limiting the false positives suffered by existing MRI techniques.

Abstract: Embodiments provide a Magnetic Resonance Imaging (MRI) technique and optionally software—collectively referred to as the “shutter-speed” model—to analyze image data of cancer patients. Embodiments provide a minimally invasive, yet precisely accurate, approach to determining whether tumors are malignant or benign by distinguishing the characteristics of contrast reagent activity in benign and malignant tumors. Exemplary embodiments provide MRI measured biomarkers for tumor malignancy determination, effectively eliminating or limiting the false positives suffered by existing MRI techniques.